Literature DB >> 28447051

Regorafenib in gastric cancer.

Elizabeth C Smyth1.   

Abstract

Entities:  

Year:  2017        PMID： 28447051      PMCID： PMC5388626          DOI： 10.21037/tgh.2017.01.07

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  24 in total

1.  Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Authors:  Peter C Thuss-Patience; Albrecht Kretzschmar; Dmitry Bichev; Tillman Deist; Axel Hinke; Kirstin Breithaupt; Yasemin Dogan; Bernhard Gebauer; Guido Schumacher; Peter Reichardt
Journal:  Eur J Cancer       Date:  2011-10       Impact factor: 9.162

2.  Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

Authors:  Josep Tabernero; Heinz-Josef Lenz; Salvatore Siena; Alberto Sobrero; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Takayuki Yoshino; Richard M Goldberg; Daniel J Sargent; Andrea Wagner; Dirk Laurent; Michael Teufel; Michael Jeffers; Axel Grothey; Eric Van Cutsem
Journal:  Lancet Oncol       Date:  2015-07-13       Impact factor: 41.316

3.  Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

Authors:  Jung Hun Kang; Soon Il Lee; Do Hyoung Lim; Keon-Woo Park; Sung Yong Oh; Hyuk-Chan Kwon; In Gyu Hwang; Sang-Cheol Lee; Eunmi Nam; Dong Bok Shin; Jeeyun Lee; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Se Hoon Park
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

4.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

5.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

6.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Authors:  Hansjochen Wilke; Kei Muro; Eric Van Cutsem; Sang-Cheul Oh; György Bodoky; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Oleg Lipatov; Tae-You Kim; David Cunningham; Philippe Rougier; Yoshito Komatsu; Jaffer Ajani; Michael Emig; Roberto Carlesi; David Ferry; Kumari Chandrawansa; Jonathan D Schwartz; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2014-09-17       Impact factor: 41.316

7.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  George D Demetri; Peter Reichardt; Yoon-Koo Kang; Jean-Yves Blay; Piotr Rutkowski; Hans Gelderblom; Peter Hohenberger; Michael Leahy; Margaret von Mehren; Heikki Joensuu; Giuseppe Badalamenti; Martin Blackstein; Axel Le Cesne; Patrick Schöffski; Robert G Maki; Sebastian Bauer; Binh Bui Nguyen; Jianming Xu; Toshirou Nishida; John Chung; Christian Kappeler; Iris Kuss; Dirk Laurent; Paolo G Casali
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

8.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab.

Authors:  Charles S Fuchs; Josep Tabernero; Jiří Tomášek; Ian Chau; Bohuslav Melichar; Howard Safran; Mustapha A Tehfe; Dumitru Filip; Eldar Topuzov; Luis Schlittler; Anghel Adrian Udrea; William Campbell; Stephen Brincat; Michael Emig; Symantha A Melemed; Rebecca R Hozak; David Ferry; C William Caldwell; Jaffer A Ajani
Journal:  Br J Cancer       Date:  2016-09-13       Impact factor: 7.640
View more
  1 in total

1.  A systematic review and meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer.

Authors:  Zhi-Gang Bai; Zhong-Tao Zhang
Journal:  Onco Targets Ther       Date:  2018-10-17       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.